Table 3. Risk of incident PD in 3-year follow-up for cDDD-based subgroups.

Variables	Unadjusted model		Adjusted model
	HR (95% CI)	p-value	HR (95% CI)	p-value	Adjusted p-value †
DPP-4 use (vs. Sulfonylurea use)
Linagliptin
cDDD <75	0.70 (0.18-2.81)	0.616	0.76 (0.19-3.06)	0.700	0.868
cDDD 75-150	0.46 (0.07-3.26)	0.437	0.54 (0.08-3.89)	0.544	0.752
cDDD >150	0.84 (0.21-3.37)	0.807	0.94 (0.23-3.79)	0.930	0.895
cDDD as continuous variable	1.00 (0.99-1.01)	0.780	1.00 (0.99-1.01)	0.961	0.911
Saxagliptin
cDDD <75	0.75 (0.31-1.80)	0.518	0.78 (0.32-1.89)	0.580	0.732
cDDD 75-150	0.67 (0.22-2.07)	0.483	0.69 (0.22-2.14)	0.517	0.722
cDDD >150	0.83 (0.31-2.22)	0.709	0.94 (0.35-2.52)	0.897	0.881
cDDD as continuous variable	0.99 (0.98-1.02)	0.523	1.00 (0.99-1.01)	0.694	0.819
Sitagliptin
cDDD <75	1.14 (0.82-1.57)	0.439	1.02 (0.73-1.41)	0.928	0.905
cDDD 75-150	1.20 (0.82-1.77)	0.343	1.16 (0.79-1.70)	0.450	0.642
cDDD >150	1.34 (0.99-1.82)	0.059	1.37 (1.01-1.87)	0.043	0.131
cDDD as continuous variable	1.01 (0.99-1.02)	0.052	1.01 (1.01-1.02)	0.047	0.130
Vildagliptin
cDDD <75	0.79 (0.39-1.59)	0.514	0.87 (0.43-1.76)	0.701	0.827
cDDD 75-150	0.71 (0.23-2.21)	0.553	0.80 (0.26-2.50)	0.700	0.827
cDDD >150	1.23 (0.46-3.3)	0.677	1.43 (0.53-3.85)	0.476	0.715
cDDD as continuous variable	1.00 (0.99-1.01)	0.859	1.00 (0.99-1.01)	0.529	0.709

^†Adjusted p-value obtained through the Bonferroni adjustment test.